secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clearside Biomedical, Inc. (CLSDQ)
CIK:        0001539029
Form:       8-K
Filed at:   2023-02-02T23:59:59+00:00
Accession:  0001193125-23-022182
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Positive OASIS extension results: 67% of wet AMD patients went ≥6 months without retreatment; cash $48.3M
--------------------------------------------------------------------------------

- 67% of extension participants (8/12) went ≥6 months without additional treatment; 50% went >6 months.
- Treatment burden reduced 77-85% vs. average monthly injections prior to CLS-AX administration.
- No serious adverse events, inflammation, vasculitis, or vascular occlusion; excellent safety profile.
- Planned initiation of Phase 2b ODYSSEY trial in Q1 2023 with primary endpoint readout mid-2024.
- Preliminary unaudited cash and cash equivalents of $48.3M as of December 31, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1539029/000119312523022182/0001193125-23-022182-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1539029/000119312523022182/d425744d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-022182

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer